Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 5 records in total 5
    records per page




    The transcriptomic profiling of COVID-19 compared to SARS, MERS, Ebola, and H1N1

    Authors: Alsamman M Alsamman; Hatem Zayed

    doi:10.1101/2020.05.06.080960 Date: 2020-05-08 Source: bioRxiv

    COVID-19 pandemic is a global crisis that threatens our way of life. As of April 29, 2020, COVID-19 has claimed more than 200,000 lives, with a global mortality rate of ~7% and recovery rate of ~30%. Understanding the interaction of cellular targets to the SARS-CoV2 infection MESHD is crucial for therapeutic development. Therefore, the aim of this study was to perform a comparative analysis of transcriptomic signatures of infection of COVID-19 compared to different respiratory viruses (Ebola, H1N1, MERS-CoV MESHD, and SARS-CoV MESHD), to determine unique anti-COVID1-19 gene signature. We identified for the first time molecular pathways for Heparin-binding, RAGE, miRNA, and PLA2 inhibitors, to be associated with SARS-CoV2 infection MESHD. The NRCAM and SAA2 that are involved in severe inflammatory response, and FGF1 and FOXO1 genes, which are associated with immune regulation, were found to be associated with a cellular gene response to COVID-19 infection MESHD. Moreover, several cytokines, most significantly the IL-8, IL-6, demonstrated key associations with COVID-19 infection MESHD. Interestingly, the only response gene that was shared between the five viral infections was SERPINB1. The PPI study sheds light on genes with high interaction activity that COVID-19 shares with other viral infections MESHD. The findings showed that the genetic pathways associated with Rheumatoid arthritis HP Rheumatoid arthritis MESHD, AGE TRANS-RAGE signaling system, Malaria, Hepatitis B MESHD Hepatitis HP B, and Influenza A were of high significance. We found that the virogenomic transcriptome of infection MESHD, gene modulation of host antiviral responses, and GO terms of both COVID-19 and Ebola are more similar compared to SARS, H1N1, and MERS. This work compares the virogenomic signatures of highly pathogenic viruses and provides valid targets for potential therapy against COVID-19.

    Network theoretic analysis of JAK/STAT pathway and extrapolation to drugs and viruses including COVID-19

    Authors: Arindam Banerjee; Rudra Prosad Goswami; Moumita Chatterjee

    doi:10.21203/rs.3.rs-25845/v1 Date: 2020-04-28 Source: ResearchSquare

    Whenever some phenomenon can be represented as a graph or a network it seems pertinent to explore how much the mathematical properties of that network impact the phenomenon. In this study we explore the same philosophy in the context of immunology. Our objective was to assess the correlation of “size” (number of edges and minimum vertex cover) of the JAK/STAT network with treatment effect in rheumatoid arthritis HP rheumatoid arthritis MESHD ( RA MESHD), phenotype of viral infection MESHD and effect of immunosuppressive agents on a system infected with the coronavirus. We extracted the JAK/STAT pathway from Kyoto Encyclopedia of Genes and Genomes (KEGG, hsa04630). The effects of the following drugs, and their combinations, commonly used in RA MESHD were tested: methotrexate, prednisolone, rituximab, tocilizumab, tofacitinib and baricitinib. Following viral systems were also tested for their ability to evade the JAK/STAT pathway: Measles, Influenza A, West Nile virus, Japanese B virus, Yellow Fever virus MESHD Fever HP virus, respiratory syncytial virus, Kaposi’s sarcoma virus MESHD sarcoma HP virus, Hepatitis HP Hepatitis MESHD B and C virus, cytomegalovirus, Hendra and Nipah virus MESHD and Coronavirus. Good correlation of edges and minimum vertex cover with clinical efficacy were observed (for edge, rho= -0.815, R2= 0.676, p=0.007, for vertex cover rho= -0.793, R2= 0.635, p=0.011). In the viral systems both edges and vertex cover were associated with acuteness of viral infections MESHD. In the JAK/STAT system already infected with coronavirus, maximum reduction in size was achieved with baricitinib. To conclude, algebraic and combinatorial invariant of a network may explain its biological behaviour. At least theoretically, baricitinib may be an attractive target for treatment of coronavirus infection MESHD.

    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis HP cirrhosis MESHD: A multicenter cohort study

    Authors: Xiaolong Qi; Yanna Liu; Jonathan A. Fallowfield; Jitao Wang; Jianwen Wang; Xinyu Li; Jindong Shi; Hongqiu Pan; Shengqiang Zou; Hongguang Zhang; Zhenhuai Chen; Fujian Li; Yan Luo; Mei Mei; Huiling Liu; Zhengyan Wang; Jinlin Li; Hua Yang; Huihua Xiang; Xiaodan Li; Tao Liu; Ming-Hua Zheng; Chuan Liu; Yifei Huang; Dan Xu; Xiaoguo Li; Ning Kang; Qing He; Ye Gu; Guo Zhang; Chuxiao Shao; Dengxiang Liu; Lin Zhang; Xun Li; Norifumi Kawada; Zicheng Jiang; Fengmei Wang; Bin Xiong; Tetsuo Takehara; Don C. Rockey; COVID-Cirrhosis-CHESS Group

    doi:10.1101/2020.04.24.20072611 Date: 2020-04-28 Source: medRxiv

    Background: Patients with pre-existing cirrhosis HP cirrhosis MESHD are considered at increased risk of severe coronavirus disease MESHD 2019 (COVID-19) but the clinical course in these patients has not yet been reported. This study aimed to provide a detailed report of the clinical characteristics and outcomes among COVID-19 patients with pre-existing cirrhosis HP cirrhosis MESHD. Methods: In this retrospective, multicenter cohort study, we consecutively included all adult TRANS inpatients with laboratory-confirmed COVID-19 and pre-existing cirrhosis HP cirrhosis MESHD that had been discharged or had died by 24 March 2020 from 16 designated hospitals in China. Demographic, clinical, laboratory and radiographic findings on admission, treatment, complications during hospitalization and clinical outcomes were collected and compared between survivors and non-survivors. Findings: Twenty-one patients were included in this study, of whom 16 were cured and 5 died in hospital. Seventeen patients had compensated cirrhosis HP cirrhosis MESHD and hepatitis HP hepatitis MESHD B virus infection was the most common etiology. Lymphocyte and platelet counts were lower, and direct bilirubin levels were higher in patients who died than those who survived (p= 0.040, 0.032, and 0.006, respectively). Acute respiratory distress HP respiratory distress MESHD syndrome and secondary infection MESHD were both the most frequently observed complications. Only one patient developed acute on chronic liver failure MESHD. Of the 5 non-survivors, all patients developed acute respiratory distress syndrome MESHD respiratory distress HP syndrome and 2 patients progressed to multiple organ dysfunction syndrome MESHD. Interpretation: Lower lymphocyte and platelet counts, and higher direct bilirubin level might represent poor prognostic indicators in SARS-CoV-2-infected MESHD patients with pre-existing cirrhosis HP cirrhosis MESHD.

    Clinical Characteristics Hospitalized Patients with SARS-Cov-2 and HBV Co-infection MESHD

    Authors: Xiaoping Chen; Qunqun Jiang; Zhiyong Ma; Jiaxin Ling; Wenjia Hu; Qian Cao; Pingzheng Mo; Rongrong Yang; Shicheng Gao; Xien Gui; Yong Xiong; Jinlin Li; Yongxi Zhang

    doi:10.1101/2020.03.23.20040733 Date: 2020-03-27 Source: medRxiv

    Background & Aims The coronavirus disease MESHD 2019 (COIVD-19) caused by SARS-CoV-2 has been characterized as a pandemic, which causes a serious public health challenge in the world. A very large group of patients infected by HBV has been reported worldwide, especially in China. In order to answer whether specific treatment strategy on the patients coinfected with HBV and SARS-CoV-2, it requires profound understanding of the clinical characteristics on those patients. However, the impacts of SARS-CoV-2 infection MESHD on HBV patients remain largely unknown. Approach & Results In this retrospective investigation, we included 123 COVID-19 patients admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from January 5 to March 7, 2020. All enrolled patients are the laboratory confirmed COVID-19 pneumonia HP pneumonia MESHD cases according to the criteria reported previously. A total of 123 patients were analyzed for their Clinical records, laboratory results including the diagnosis of HBV infection MESHD and liver function. Among 123 confirmed COVID-19 patients, the mean age TRANS was 51 years old and 59.3% were females TRANS (73/123). Fifteen were previously HBV infected MESHD patients, 66.7% of them were males TRANS (10/15), patients with HBV infection MESHD appeared to have a higher incidence of liver cirrhosis MESHD cirrhosis HP and an increased level of total bilirubin. Seven (46.7%) patients with HBV infection MESHD were defined as severe cases, while the severity rate was 24.1% for the patients without HBV infection MESHD (26/108). The mortality of patients with HBV infection MESHD was 13.3% (2/15) compared to 2.8% (3/108) for the patients without HBV infection MESHD. Conclusions SARS-CoV-2 infection MESHD may cause liver function damage MESHD in COVID-19 cases and the patients with HBV infection MESHD are likely to have more severe disease outcome.

    Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis

    Authors: Wei-jie Guan; Wen-hua Liang; Yi Zhao; Heng-rui Liang; Zi-sheng Chen; Yi-min Li; Xiao-qing Liu; Ru-chong Chen; Chun-li Tang; Tao Wang; Chun-quan Ou; Li Li; Ping-yan Chen; Ling Sang; Wei Wang; Jian-fu Li; Cai-chen Li; Li-min Ou; Bo Cheng; Shan Xiong; Zheng-yi Ni; Yu Hu; Jie Xiang; Lei Liu; Hong Shan; Chun-liang Lei; Yi-xiang Peng; Li Wei; Yong Liu; Ya-hua Hu; Peng Peng; Jian-ming Wang; Ji-yang Liu; Zhong Chen; Gang Li; Zhi-jian Zheng; Shao-qin Qiu; Jie Luo; Chang-jiang Ye; Shao-yong Zhu; Lin-ling Cheng; Feng Ye; Shi-yue Li; Jin-ping Zheng; Nuo-fu Zhang; Nan-shan Zhong; Jian-xing He

    doi:10.1101/2020.02.25.20027664 Date: 2020-02-27 Source: medRxiv

    Objective: To evaluate the spectrum of comorbidities and its impact on the clinical outcome in patients with coronavirus disease MESHD 2019 (COVID-19). Design: Retrospective case studies Setting: 575 hospitals in 31 province/autonomous regions/provincial municipalities across China Participants: 1,590 laboratory-confirmed hospitalized patients. Data were collected from November 21st, 2019 to January 31st, 2020. Main outcomes and measures: Epidemiological and clinical variables (in particular, comorbidities) were extracted from medical charts. The disease severity was categorized based on the American Thoracic Society guidelines for community-acquired pneumonia HP pneumonia MESHD. The primary endpoint was the composite endpoints, which consisted of the admission to intensive care unit (ICU), or invasive ventilation, or death MESHD. The risk of reaching to the composite endpoints was compared among patients with COVID-19 according to the presence and number of comorbidities. Results: Of the 1,590 cases, the mean age TRANS was 48.9 years. 686 patients (42.7%) were females TRANS. 647 (40.7%) patients were managed inside Hubei province, and 1,334 (83.9%) patients had a contact history of Wuhan city. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints. 399 (25.1%) reported having at least one comorbidity. 269 (16.9%), 59 (3.7%), 30 (1.9%), 130 (8.2%), 28 (1.8%), 24 (1.5%), 21 (1.3%), 18 (1.1%) and 3 (0.2%) patients reported having hypertension HP hypertension MESHD, cardiovascular diseases MESHD, cerebrovascular diseases MESHD, diabetes MESHD, hepatitis HP hepatitis MESHD B infections, chronic HP chronic obstructive pulmonary disease MESHD obstructive pulmonary disease, chronic HP chronic kidney diseases MESHD, malignancy and immunodeficiency MESHD immunodeficiency HP, respectively. 130 (8.2%) patients reported having two or more comorbidities. Patients with two or more comorbidities had significantly escalated risks of reaching to the composite endpoint compared with those who had a single comorbidity, and even more so as compared with those without (all P<0.05). After adjusting for age TRANS and smoking status, patients with COPD MESHD (HR 2.681, 95%CI 1.424-5.048), diabetes MESHD (HR 1.59, 95%CI 1.03-2.45), hypertension HP hypertension MESHD (HR 1.58, 95%CI 1.07-2.32) and malignancy MESHD (HR 3.50, 95%CI 1.60-7.64) were more likely to reach to the composite endpoints than those without. As compared with patients without comorbidity, the HR (95%CI) was 1.79 (95%CI 1.16-2.77) among patients with at least one comorbidity and 2.59 (95%CI 1.61-4.17) among patients with two or more comorbidities. Conclusion: Comorbidities are present in around one fourth of patients with COVID-19 in China, and predispose to poorer clinical outcomes.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.